Trial Profile
A phase III clinical trial of fixed dose combination Cefepime / AAI101
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 06 Sep 2018
Price :
$35
*
At a glance
- Drugs Cefepime/enmetazobactam-Allecra-Therapeutics (Primary)
- Indications Gram-negative infections
- Focus Therapeutic Use
- 23 Aug 2018 According to an Allecra Therapeutics media release, trial will be executed in 19 countries and in 114 trial sites, with more than 1,000 patients involved.
- 23 Aug 2018 According to an Allecra Therapeutics media release, company is ready to commence this study.
- 16 Feb 2018 New trial record